Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, 8/16/11, traders not investors dominate markets

The 6 W’s: Who, what, where, when, why and what of it…

By 10:45am, stocks on Tuesday retreated after a 3 session advance, as data illustrating a slowdown in Germany’s economy dampened optimism from a rise in US industrial production. Stepping back after its biggest 3 day percentage gain since 3/09, the Dow fell 65.88 points to 11,417.02, with 25 of its 30 components losing ground. The NASDAQ lost 25.04 points to 2,530.16.

The NASDAQ is now DOWN -32.77 (-1.28%) to 2,5232.43. The Dow is also DOWN -88.43 (-0.77%) to 11,360.52. The DOW is still UNDER 12,000.

Regenerative medicine/stem cell universe shares on 8/16/11 are “pausing … post yesterday’s run-up as traders take any appreciation and head for the exit with small upticks”

Mid-Day Movers … NeoStem (AMEX: NBS) and Opexa (NASDAQ:OPXA) 

 

What’s new in the regenerative medicine/stem cell market … Confidence is waning and I am not feeling better … maybe, I should just stay in bed … and wait for the market to turn … when?

 

Aastrom Biosciences (ASTM) Q2/11 Results: A net loss for Q2/11 was $9.957M, or $0.26 per share compared to Q2/10 of $3.76M or $0.13 for Q2/10. Guidance: ASTM announced they will be spending $7M per quarter (Q/3 & Q/4/11. As of 6/30/11, ASTM had $18.5M in cash and cash equivalents.

 

NeoStem (AMEX: NBS) Raised to ‘Speculative “Buy” at WBB Securities